The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Molecular Pediatric Oncology

PI Daniel Bexell

Our research

Our overall aims are to unravel mechanisms leading to metastasis and treatment resistance of childhood cancer neuroblastoma, and to test compounds targeting aggressive neuroblastoma. We have recently established and characterized several neuroblastoma orthotopic patient-derived xenografts (PDXs). These PDXs retain the genotype, phenotype, tumorigenic, and metastatic properties of the tumors from which they were derived, making them authentic models for studying and targeting neuroblastoma metastasis and resistance. Our projects encompass studies on basic tumor biology as well as translational and preclinical studies with the aim to find novel treatments. We perform molecular and functional studies of primary and metastatic tumor cells, as well as in vitro and in vivo drug testing using PDXs as model system. Discovery of novel strategies to inhibit treatment-resistant metastatic tumors can increase survival and decrease side effects for high-risk neuroblastoma patients.

Picture of Daniel Bexell in a black sweater standing in the lab corridor.

Daniel Bexell

Phone: +46 46 222 64 23
Mail: daniel [dot] bexell [at] med [dot] lu [dot] se

Personal Research Portal page

Team members

Kristina Aaltonen

Aleksandra Adamska

Javanshir Esfandyari

Erick Muciño Olmos

Katarzyna Radke

Alexandra Seger

Caroline Jansson

Hanna Chahin

Dora Adamic

Johannes Nilsson

Katarina Turesson


Click on the name to visit their personal research portal page.